Arrowhead Pharmaceuticals raises ~$250M via equity offering of 7.8M shares through Jefferies

ARROWHEAD PHARMACEUTICALS, INC.

Entered Open Market Sale Agreement with Jefferies LLC to sell up to 7,807,620 shares of common stock.
Estimated gross proceeds of ~$250 million after discounts, commissions, and expenses.
Offering closed on December 2, 2022; shares issued under shelf registration statement on Form S-3.
Company agreed to indemnify Jefferies against certain liabilities under the Securities Act.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ARROWHEAD PHARMACEUTICALS, INC. entered into Open Market Sale Agreement with Jefferies LLC valued at approximately $250 million (effective 2022-12-02).

Action: entry
Agreement: atm program
Counterparty: Jefferies LLC
Value: approximately $250 million
Effective: 2022-12-02

Exact text from the filing

On December 2, 2022, Arrowhead Pharmaceuticals, Inc. (the “Company”) entered into an open market sale agreement (the “Open Market Sale Agreement”) with Jefferies LLC (the "Agent"), pursuant to which the Company agreed to issue and sell up to 7,807,620 shares of common stock (the “Shares”), par value $0.001 per share (the “Common Stock”). The Company estimates that gross proceeds from the offering will be approximately $250 million

View on SEC.gov

Browse all material agreements →

ARROWHEAD PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-22-031597

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.